Newsletters

Newsletters published on June 22, 2020

This activity summarizes key data from studies investigating novel agents and treatment strategies that are needed to expand therapeutic options for patients who have myelofibrosis.

For more information on the evolving treatment landscape in myelofibrosis, please view the CE Education activity here.

Newsletters published on March 11, 2020

In this activity, two experts discuss recent data on JAK2 inhibitors such as the approval of fedratinib and promising emerging data from trials evaluating pacritinib and momelotinib.

For more information on the evolving treatment landscape in myelofibrosis, please view the CE Education activity here.

Newsletters published on February 28, 2020

Case studies presented by Dr. Bose highlight emerging treatment options for patients with myelofibrosis after JAK inhibitor "failure."

For more information on managing your patients with myelofibrosis, please view the CE Education activity here

Newsletters published on February 13, 2020

This newsletter discusses approaches to inhibit JAK2, as well as other combination approaches with ruxolitinib to maximize efficacy for patients with myelofibrosis.

For more information on managing your patients with myelofibrosis, please view the CE Education activity here

Newsletters published on December 10, 2019
This newsletter discusses classic myeloproliferative neoplasms, such as ET, PV and PMF; including how they interact, evolve and what treatment selections are available.

For more information on managing your patients with myelofibrosis, please view the CE Education activity here


Results 1 - 5 of 5